Cipla spurts as its arm receives USFDA approval to market generic Bupropion Hydrochloride tablets

31 Aug 2016 Evaluate

Cipla is currently trading at Rs 582.25, up by 5.65 points or 0.98% from its previous closing of Rs 576.60 on the BSE.

The scrip opened at Rs 580.05 and has touched a high and low of Rs 586.50 and Rs 580.05 respectively. So far 49350 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 704.75 on 29-Oct-2015 and a 52 week low of Rs. 458.25 on 25-May-2016.

Last one week high and low of the scrip stood at Rs 586.50 and Rs 560.00 respectively. The current market cap of the company is Rs. 46790.22 crore.

The promoters holding in the company stood at 37.47%, while Institutions and Non-Institutions held 34.54% and 27.99% respectively.

Cipla’s US subsidiary, InvaGen Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) to market a generic Bupropion Hydrochloride extended release tablets (XL), 150 mg and 300 mg, used for treatment of major depressive disorder. The company's tablets are generic versions of Valeant's Wellbutrin XL tablets in the same strengths. Wellbutrin XL tablets and generic equivalents had US sales of approximately $792 million for the 12 month period ending June 2016, according to IMS Health.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Cipla Share Price

1517.00 17.90 (1.19%)
19-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.10
Dr. Reddys Lab 1278.90
Cipla 1517.00
Zydus Lifesciences 919.85
Lupin 2125.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×